WeTrials
Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

What is this study?

This clinical trial is testing a new experimental drug called ETX-19477 for adults with advanced solid tumors, including breast, ovarian, and prostate cancers. Researchers want to find the safest and most effective dose of this medicine to help fight cancer.

Who can participate?

Adults aged 18 and older with advanced, incurable, or spreading solid tumors who are able to maintain their normal daily activities may join. Priority is often given to patients with specific genetic changes like BRCA2, while those with untreated brain tumors or certain digestive conditions cannot take part.

What will happen?

Participants will receive the study medication, ETX-19477, while doctors closely monitor their safety, side effects, and how well the treatment works. Regular check-ups and imaging scans will be used to track tumor changes throughout the study.

Where and when?

This study is currently recruiting patients at various locations, including medical centers in Phoenix, Arizona, New Haven, Connecticut, and Jacksonville, Florida. More sites may also be available.

Key Points
  • 1Testing an experimental cancer drug called ETX-19477
  • 2Open to adults with advanced solid tumors like breast, ovarian, and prostate cancer
  • 3Currently active and recruiting participants at multiple medical centers

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced or Metastatic Solid TumorsBreast CancerOvarian CancerProstate CancerEpithelial Ovarian CancerBRCA2 MutationER+ Breast CancerCastrate Resistant Prostate CancerBRCA1 MutationBRCA MutationEndometrial CancerColorectal CancerGastric Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.